Joseph F. Fraumeni Jr.

Last updated
Joseph F. Fraumeni Jr.
Fraumeni.jpg
Born (1933-04-01) April 1, 1933 (age 91)
Alma mater Harvard College
Duke University
Harvard School of Public Health
Awards Charles S. Mott Prize
Scientific career
Institutions National Cancer Institute

Joseph F. Fraumeni Jr. (born April 1, 1933) is an American physician and cancer researcher. Born in Boston, [1] he received an A.B. from Harvard College, an M.D. from Duke University, and an M.Sc. in epidemiology from the Harvard School of Public Health. He completed his medical residency at Johns Hopkins Hospital and Memorial Sloan Kettering Cancer Center. He then joined the National Cancer Institute at the National Institutes of Health in 1962 as a commissioned officer of the U.S. Public Health Service, becoming the founding Director of the Division of Cancer Epidemiology and Genetics in 1995. He stepped down from this position in 2012 to become a senior investigator and advisor to the National Cancer Institute.

One of Fraumeni's research accomplishments was the identification in 1969 with Frederick Pei Li of four families with an increased susceptibility to multiple forms of cancer in children and young adults. [2] Tracing these families and 20 others for twenty years [3] led to the characterization of what became known as Li–Fraumeni syndrome and the discovery in 1990 of inherited mutations of the tumor suppressor gene, p53, as the underlying mechanism in most affected families. [4]

Awards

Fraumeni has been recognized by numerous honors and awards for his research into the genetic and environmental determinants of cancer. Among them are the Abraham Lilienfeld Award from the American College of Epidemiology, John Snow Award from the American Public Health Association, James D. Bruce Award from the American College of Physicians, Nathan Davis Award from the American Medical Association, Charles S. Mott Prize (with F.P. Li) from the General Motors Cancer Research Foundation, Medal of Honor from the International Agency for Research on Cancer and the American Cancer Society, and Lifetime Achievement Award from the American Association for Cancer Research. Fraumeni is an elected member of the National Academy of Sciences, National Academy of Medicine, Association of American Physicians, and American Academy of Arts and Sciences. He has over 900 scientific publications, including several books on the causes and prevention of cancer.

Related Research Articles

<span class="mw-page-title-main">Li–Fraumeni syndrome</span> Autosomal dominant cancer syndrome

Li–Fraumeni syndrome is a rare, autosomal dominant, hereditary disorder that predisposes carriers to cancer development. It was named after two American physicians, Frederick Pei Li and Joseph F. Fraumeni Jr., who first recognized the syndrome after reviewing the medical records and death certificates of 648 childhood rhabdomyosarcoma patients. This syndrome is also known as the sarcoma, breast, leukaemia and adrenal gland (SBLA) syndrome.

<span class="mw-page-title-main">Frederick Pei Li</span> Chinese-American physician (1940–2015)

Frederick Pei Li was a Chinese-American physician. He is most famous for his discovery, together with his colleague Joseph Fraumeni, of Li–Fraumeni syndrome, which is caused by germline mutations of the p53 tumor suppressor gene and genetically predisposes families to high rates of cancer.

The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 52,000 members in 130 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300.

Paolo Boffetta is an Italian epidemiologist. He is doing research on cancer and other chronic diseases, where he contributed to the understanding of the role of occupation, environment, alcohol, smoking and nutrition in disease development.

Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from July 2007 to November 2018. He is board certified in internal medicine and medical oncology and is a Master of the American College of Physicians, Fellow of the American Society of Clinical Oncology, and a Fellow of the American College of Epidemiology. He is a member of the Institute of Medicine now known as the National Academy of Medicine.

<span class="mw-page-title-main">Haroutune Armenian</span> Armenian-American academic

Haroutune Armenian, is a Lebanese born Armenian-American academic, physician, doctor of public health (1974), Professor, President of the American University of Armenia, President Emeritus, American University of Armenia. Professor in Residence, UCLA, Fielding School of Public Health.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Webster K. "Web" Cavenee is the Director of Strategic Alliances in Central Nervous System Cancers at the Ludwig Institute for Cancer Research and Distinguished Professor at the University of California, San Diego. He was the Director of the Ludwig Institute for Cancer Research until 2015 when it was taken over by Richard Kolodner. His laboratory studies gene mutations in cancer, most notably in EGFR and glioblastoma multiforme.

Charles J. Sherr is the chair of the Tumor Cell Biology Department at St. Jude Children's Research Hospital. He studies tumor suppressor genes and cell division.

Professor Carol L. Prives FRS is the Da Costa Professor of Biological Sciences at Columbia University. She is known for her work in the characterisation of p53, an important tumor suppressor protein frequently mutated in cancer.

<span class="mw-page-title-main">Curtis C. Harris</span> American cancer researcher

Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.

Guillermina 'Gigi' Lozano is an American geneticist. She is a professor at University of Texas MD Anderson Cancer Center. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression.

<span class="mw-page-title-main">Louise A. Brinton</span> American epidemiologist

Louise Annette Brinton is an American epidemiologist. She was a senior investigator, Chief of the Hormonal and Reproductive Epidemiology Branch, and the first Scientific Advisor for International Activities of the National Cancer Institute Division of Cancer Epidemiology and Genetics.

Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.

<span class="mw-page-title-main">Debra T. Silverman</span> American biostatistician and cancer epidemiologist

Debra Toby Silverman is an American biostatistician and epidemiologist specialized in bladder cancer epidemiology and the carcinogenicity of diesel exhaust. Silverman is the chief of the occupational and environmental epidemiology branch at the National Cancer Institute.

<span class="mw-page-title-main">Shelia Hoar Zahm</span> American epidemiologist

Shelia Hoar Zahm is an American cancer epidemiologist specialized in pesticides and cancer, the etiology of non-Hodgkin lymphoma, and occupational cancer among women. She was deputy director of the National Cancer Institute's division of cancer epidemiology and genetics from 1998 to 2011.

<span class="mw-page-title-main">Patricia Hartge</span>

Patricia A. Hartge is an American cancer epidemiologist who conducted genome-wide association studies on ovarian cancer, non-Hodgkin lymphoma, melanoma, and other malignancies. From 1996 to 2013, Hartge was deputy director of the epidemiology and biostatistics program in the division of cancer epidemiology and genetics at the National Cancer Institute.

Mitchell H. Gail is an American physician-scientist and biostatistician. He is a distinguished investigator at the National Cancer Institute.

Lindsay McOmber Morton is an American cancer epidemiologist who researches genetic susceptibility to second cancers. She is the acting chief of the radiation epidemiology branch and head of its cancer survivorship research unit at the National Cancer Institute.

References

  1. Hoover, Robert N. (2013). "A Conversation with Joseph F. Fraumeni, Jr". Epidemiology. 24 (6): 929–933. doi: 10.1097/EDE.0b013e3182a56987 . PMID   24076995. S2CID   238402678.
  2. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969:71:747-752.
  3. Li FP, Fraumeni JF Jr., Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988:48:5358-5362.
  4. Malkin D, Li FP, Strong LC, Fraumeni, JF Jr., Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky, MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990:250: 1233–1238.